Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19.
Br J Pharmacol
; 177(21): 4899-4920, 2020 11.
Article
in English
| MEDLINE | ID: covidwho-991236
ABSTRACT
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of the novel coronavirus disease 2019 (COVID-19), a highly pathogenic and sometimes fatal respiratory disease responsible for the current 2020 global pandemic. Presently, there remains no effective vaccine or efficient treatment strategies against COVID-19. Non-steroidal anti-inflammatory drugs (NSAIDs) are medicines very widely used to alleviate fever, pain, and inflammation (common symptoms of COVID-19 patients) through effectively blocking production of prostaglandins (PGs) via inhibition of cyclooxyganase enzymes. PGs can exert either proinflammatory or anti-inflammatory effects depending on the inflammatory scenario. In this review, we survey the potential roles that NSAIDs and PGs may play during SARS-CoV-2 infection and the development and progression of COVID-19. LINKED ARTICLES This article is part of a themed issue on The Pharmacology of COVID-19. To view the other articles in this section visit http//onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Coronavirus Infections
/
Betacoronavirus
Type of study:
Observational study
Topics:
Vaccines
Limits:
Animals
/
Humans
Language:
English
Journal:
Br J Pharmacol
Year:
2020
Document Type:
Article
Affiliation country:
Bph.15206
Similar
MEDLINE
...
LILACS
LIS